Skip to main content

Clinical Trials › NCT06451159

Active, Not RecruitingPhase 1

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Sponsored by Bruce Cree

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
10
Target enrollment
1
U.S. states
Jun 2024
Start date
Feb 2027
Expected completion

Interventions / Treatments

KYV-101 (Biological) - 0.33 ×10^8 cellsKYV-101 (Biological) - 1 ×10^8 cellsChemotherapy: cyclophosphamide (CYC)Chemotherapy: fludarabine (FLU)

Conditions studied

Progressive Multiple Sclerosis

Where this trial is running (1 site)

San Francisco

Participating MS centers on MS Buddy (1)

MS centers in California

Compare treatment centers near a trial site by center type, providers and trials.

View California centers

More Phase 1 trials

Browse all Phase 1 MS trials
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play